What is it about?
101BHG-D01 is a novel selective anti-muscarinic (M) 3 receptor blocking drug. 101BHG-D01 nasal spray is intended to be used to relieve sneezing and runny nose symptoms caused by allergic rhinitis. In this study, we examined the plasma pharmacokinetics, tissue distribution and major excretion mode of 101BHG-D01 in Beagle dogs and rats following nasal spray and intranasal administration respectively using HPLC-MS/MS. We found that the pharmacokinetics of 101BHG-D01 were linear in dogs. 101BHG-D01 entered bloodstream rapidly following nasal spray. Its plasma half-life was approximately 6 h, and resided at least 24 h in the body. Moreover, 101BHG-D01 retained a significant amount in the nasal cavity. Finally, we found that 101BHG-D01 was eliminated mainly in the form of stools in rats.
Photo by Curology on Unsplash
Why is it important?
We provided pertinent reference information for the design and optimization of drug delivery regimens for clinical trials.
Read the Original
This page is a summary of: Pharmacokinetics and Tissue Distribution of Nasal Spray of a Novel Muscarinic
Receptor Blocker, 101BHG-D01, in Dogs and Rats, Current Drug Metabolism, November 2022, Bentham Science Publishers, DOI: 10.2174/1389200224666221201123254.
You can read the full text:
The following have contributed to this page